Pharmacologic treatment of cognition in Alzheimer's dementia
- 1 July 1998
- journal article
- review article
- Published by Wolters Kluwer Health in Neurology
- Vol. 51 (1_suppl_1) , S36-S44
- https://doi.org/10.1212/wnl.51.1_suppl_1.s36
Abstract
Much of the treatment research and development for Alzheimer's disease(AD) in recent years has been based on the cholinergic hypothesis. Cholinesterase inhibition has been shown to improve the symptoms of mild to moderate AD. Two cholinesterase inhibitors (CIs) are now available and two more may be available shortly. Free radical inhibitors, estrogen, and anti-inflammatory drugs may also delay the onset and slow progression of AD. Combination therapies employing CIs and these other drugs may prove successful in the future.Keywords
This publication has 35 references indexed in Scilit:
- Treatment of Men with Erectile Dysfunction with Transurethral AlprostadilNew England Journal of Medicine, 1997
- Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)Neurology, 1996
- Effects of growth hormone and prolactin immune development and functionLife Sciences, 1995
- IntroductionAlzheimer Disease & Associated Disorders, 1994
- EDITORIALNeuroimmunomodulation, 1994
- CNS white matter can be altered to support neuronal outgrowthJournal of Neuroscience Research, 1994
- Neurotrophins in the Central Nervous SystemReviews in the Neurosciences, 1992
- Pyrophosphate‐dependent phosphofructokinase, an anaerobic glycolytic enzyme?FEBS Letters, 1991
- Leukemia Following Chemotherapy for Ovarian CancerNew England Journal of Medicine, 1990
- Cushing's Syndrome in Patients with the Zollinger–Ellison SyndromeNew England Journal of Medicine, 1986